Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos)
Anido, Urbano (Complejo Hospitalario Universitario de Santiago de Compostela)
Climent, M.Á. (Instituto Valenciano de Oncología (IVO))
Gonzalez-Billalabeitia, E. (Universidad Católica San Antonio de Murcia-UCAM)
Lainez, N. (Complejo Hospitalario de Navarra)
Lambea, Julio (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Mendez-Vidal, M.J. (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Montesa, Álvaro (Hospital Regional Universitario de Málaga)
Rodriguez, A. (Hospital Universitario de León)
Zambrana, C. (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes))
González-del-Alba, A. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted ⩾7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations. In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Abiraterone acetate ; Androgen-deprivation therapy ; Chemotherapy ; Enzalutamide ; Metastatic castration-resistant prostate cancer ; Radium-223
Publicat a:	Therapeutic Advances in Medical Oncology, Vol. 12 (2020) , ISSN 1758-8359

DOI: 10.1177/1758835920920067
PMID: 33014145

12 p, 144.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats